News

Qilu Pharmaceutical Acquired an Exclusive Right for the Development and Commercialization of Vicineum™ in Greater China

ABOUT US

News

Qilu Pharmaceutical Acquired an Exclusive Right for the Development and Commercialization of Vicineum™ in Greater China

Release time：

2021-07-31

Qilu Pharmaceutical announced an exclusive license agreement with Sesen Bio for the development and commercialization of Vicineum™ in Greater China on July 31^st, 2020. Vicineum™ is used for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) and other types of cancer.

“Qilu is well-respected for their commercialization and manufacturing expertise, and this partnership marks an important milestone in realizing what we believe to be a significant market opportunity for Vicineum” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

“Sesen is the ideal partner for us with the unique scientific research advantage in NMIBC” said Yan Li, chief executive officer of Qilu Pharmaceutical. “We look forward to working with Sesen and The National Medical Products Administration to bring Vicineum to patients who urgently need better therapies for BCG unresponsive non-muscle invasive bladder cancer in China.”

Qilu Pharmaceutical Ranked No. 9 among Top 100 Chinese Pharmaceutical Companies

Abiraterone Acetate Tablets exported to US

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”